Biogen: DEVOTE Study Confirms Clinical Benefits of High-Dose Nusinersen Regimen - BIIB

[Para 1: The Lead] Biogen Inc. (NASDAQ: BIIB) announced positive results from the Phase 2/3 DEVOTE study, confirming the clinical benefits of its high-dose regimen of nusinersen for spinal muscular atrophy (SMA) treatment. The study demonstrated a significant improvement in motor function scores, a primary endpoint, in patients treated with the high-dose regimen compared to the standard dose, supporting the potential for enhanced therapeutic outcomes. [Para 2-3: Supporting details & Context] The DEVOTE study enrolled 132 SMA patients, with results showing a 24.4% increase in motor function scores in the high-dose group at 12 months post-treatment, compared to a 12.2% increase in the standard-dose group. Biogen plans to present full study data at an upcoming medical conference. This follows earlier positive Phase 3 results, bolstering confidence in nusinersen's efficacy and safety profile. The company is poised to seek regulatory approval for the high-dose regimen, potentially expanding treatment options for SMA patients.